The business model for antibiotics is broken. We looked at other industries facing conceptually similar challenges - particularly when the incentive for R&D is delinked from the volume of sales.
Just published in Health Economics is an article by OHE’s Adrian Towse and others on pharmaceutical pricing in middle and low income countries (MLICs).
Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health Economics in February 2015.
OHE Lunchtime Seminar with Professor Aslam H. Anis, University of British Columbia, Vancouver's Centre for Health Evaluation and Outcome Sciences and the CIHR Canadian HIV Trials Network.
On 28th November 2014 the BMJ published the Editorial “Reforming the Cancer Drug Fund”. In this editorial, Buxton, Longworth, Raftery, Sculpher and Towse argue that the CDF, with new arrangements for
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US market may evolve.
Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines?
In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health technology assessment (HTA) bodies and...
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The first blog is available...
